Rhumbline Advisers Lowers Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Rhumbline Advisers decreased its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 8.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 86,842 shares of the biopharmaceutical company's stock after selling 7,666 shares during the quarter. Rhumbline Advisers owned about 0.15% of Agios Pharmaceuticals worth $2,544,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in AGIO. AlphaCentric Advisors LLC purchased a new position in Agios Pharmaceuticals during the fourth quarter valued at $202,000. Venturi Wealth Management LLC purchased a new position in Agios Pharmaceuticals during the fourth quarter valued at $33,000. New York State Common Retirement Fund raised its stake in Agios Pharmaceuticals by 13.5% during the fourth quarter. New York State Common Retirement Fund now owns 39,093 shares of the biopharmaceutical company's stock valued at $1,285,000 after buying an additional 4,663 shares during the last quarter. Handelsbanken Fonder AB raised its stake in Agios Pharmaceuticals by 8.4% during the fourth quarter. Handelsbanken Fonder AB now owns 19,323 shares of the biopharmaceutical company's stock valued at $635,000 after buying an additional 1,500 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in Agios Pharmaceuticals during the fourth quarter valued at $1,506,000.

Analysts Set New Price Targets

A number of research analysts have issued reports on AGIO shares. Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price target for the company. Finally, Scotiabank decreased their price target on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research note on Friday, May 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $58.60.

Agios Pharmaceuticals Price Performance

AGIO stock opened at $34.30 on Monday. The stock has a market capitalization of $1.99 billion, a P/E ratio of 3.02 and a beta of 0.73. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58. The business has a fifty day moving average price of $29.76 and a 200-day moving average price of $33.41.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. The company had revenue of $8.73 million during the quarter, compared to analysts' expectations of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Activity at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the sale, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. This represents a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.93% of the stock is owned by company insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.